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Abstract 
Background: Although Attention Deficit Hyperactivity Disorder (ADHD) is a common condition for 
which pharmacotherapy is considered an effective treatment, guidelines on the treatment of ADHD 
have been challenging to implement. Considering the views of patients and caregivers involved in 
medication-taking could help shed light on these challenges.   
Objective: This review combines the findings of individual studies of medication-taking experiences 
in ADHD in order to guide clinicians to effectively share decisions about treatment. 
Methods: Five databases (MEDLINE, Embase, PsycINFO, SCOPUS and CINAHL) were systematically 
searched for relevant published research papers. Articles were assessed for quality using a Critical 
Appraisal Skills Programme checklist and synthesis was performed using meta-ethnography. 
Results: 31 papers were included in the final synthesis, comprising studies of caregivers, paediatric 
patients and adult patients across seven countries. Findings were categorised into five different 
constructs, including coming to terms with ADHD, anticipated concerns about medication, 
experiences of the effects of medication, external influences and the development of self-
management. The synthesis demonstrates that decisions surrounding medication-taking for ADHD 
evolve as the child patient enters adulthood and moves towards autonomy and self-management. In 
all parts of this journey, decisions are shaped by a series of ‘trade-offs’, where potential benefits and 
harms of medication are weighed up. 
Conclusions: This review offer a comprehensive insight into medication-taking experiences in ADHD. 
By considering the shifting locus of decision making over time and the need for individuals and 
families to reconcile a variety of external influences, primary care and mental health clinicians can 
engage in holistic conversations with their patients to share decisions effectively. 
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Introduction 
Attention Deficit Hyperactivity Disorder (ADHD) is characterized by the inability to sustain attention, 
modulate activity level, and moderate impulsive actions1. Although the resulting maladaptive 
behaviours are typically first recognised during childhood, symptoms often continue into adulthood
2
. 
Untreated ADHD has been associated with significant social and psychological sequelae
3
. Although 
pharmacotherapy is considered to be an effective treatment for ADHD
4
, recommendations vary with 
regard to the use of medications as a first line treatment
5, 6
. 
 
Despite the apparent efficacy of medications and negative consequences of untreated ADHD, rates 
of adherence to medication regimes are low, with an estimated 50% of patients choosing to 
discontinue pharmacotherapy
7
. ADHD is diagnosed based on clinical symptoms with a lack of 
objective physical examination or laboratory investigation findings and moreover, ADHD behaviours 
can overlap and co-exist with other mental health conditions1. It has also received widespread and 
often contradictory media coverage in recent years8. As such, there are likely to be a complex array 
of factors that contribute to treatment decisions.   
Medication adherence is a multidimensional phenomenon that is shaped by factors relating to the 
patient, type of treatment, condition, healthcare system and individual social circumstances9. Non-
adherence is described as unintentional when the patient wants to adhere but is unable to due to 
lack of resources or capacity. Intentional adherence, meanwhile, occurs when individuals make an 
active choice not to comply with treatment recommendations10. Research in the medical and social 
sciences has demonstrated the importance of social support in treatment adherence11. In ADHD, a 
number of factors have been recognised including general factors such as age and gender12 and 
more specific factors such as duration of treatment and the presence of side effects13.  
Shared decision-making (SDM) is a well-established approach to improving the quality of healthcare 
14, 15 that involves clinicians providing information about treatment options, and patients (or 
caregivers) providing information about values so that agreement on the best option for an 
individual patient can be reached16. ADHD treatment guidelines recognise the importance of 
individual family values, concerns and preferences when deciding on treatment options5, 6, 
emphasising that SDM is an essential component of ADHD care. Despite this, SDM during the 
treatment planning process for children newly diagnosed with ADHD has been shown to be limited17. 
There is therefore a need to support clinicians to better share decisions with ADHD patients and 
their caregivers. 
Whilst a number of qualitative studies have explored patients’ and caregivers’ perspectives on ADHD 
medication, the clinical and policy application of their findings may be limited by the variety of study 
settings and populations and the relatively small individual study sample sizes. This review sought to 
synthesise the findings of these individual studies and was driven by the following question:  How 
can clinicians effectively share decisions about treatment for ADHD?   
 
Methods 
Selection of Studies for Inclusion 
We systematically searched five databases (MEDLINE, Embase, PsycINFO, SCOPUS and CINAHL) for 
relevant papers.  These databases were chosen to maximise our ability to identify papers from both 
clinical and non-clinical journals. Search criteria comprised terms in three groups: methodology 
(search terms qualitative; focus group; interview; ethnography and thematic), focus (search terms 
medication; adherence; compliance; concordance and drug), and sample (search terms ADHD; ADD 
and attention deficit hyperactivity disorder.) These search terms were combined using Boolean logic 
terms (OR within the groups and AND between groups). The search was restricted to papers written 
in English and published in peer reviewed journals. Searches were conducted in October 2015 and 
were restricted to articles published since 1987, as this was the first use of the terminology attention 
deficit/hyperactivity disorder, appearing in the revision of the third edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III-R) 18.  It is well recognised that qualitative studies can 
be hard to identify, and that systematic reviews cannot rely on database searching alone19. In light of 
this we also manually searched bibliographies.  
All identified titles and abstracts were screened by one researcher (SL). In addition, ten percent were 
independently screened by a second researcher (MAR), with no discrepancies in selections. Studies 
that were excluded on the basis of abstracts alone typically did not use qualitative methodologies or 
did not focus on medication taking experiences. Full-text articles were obtained for all selected 
abstracts and assessed for inclusion by two researchers (SL and MAR). Inclusion criteria were:  
1. Focuses on individuals with ADHD 
2. Explores medication-taking experiences of patients and/or their caregivers 
3. Uses a qualitative methodology 
4. Original research paper published in English in a peer-reviewed journal 
 Critical Appraisal 
Papers selected for inclusion were independently appraised by two authors (SL and MAR) using the 
Critical Appraisal Skills Programme (CASP) qualitative research checklist20, an established tool for the 
appraisal of qualitative studies. Only articles scoring more than 50% were included in the synthesis.  
In light of the debate surrounding the value of critical appraisal in qualitative syntheses, papers were 
additionally assessed with regard to their relevance to our research question, using the criteria set 
out by Dixon-Woods et al21. Papers included in our synthesis were classified as either ‘Key Papers’ – 
where content closely mirrored the topic of our research question – or ‘Satisfactory Papers’ – studies 
providing a smaller contribution to our synthesis. This classification was agreed upon by two 
researchers (SL and MAR) and are presented to allow readers to recognise the relative contribution 
of individual papers to the review 
Synthesis 
Included studies were synthesised using a meta-ethnographic approach. Meta-ethnography is an 
approach to the synthesis of qualitative studies pioneered by Noblit and Hare22. It can be considered 
as similar to meta-analysis for quantitative research in that it aims to provide a comprehensive 
insight into the topic of research.  However, meta-ethnography differs from meta-analysis in that it 
seeks to interpret the results of individual studies in order to create a new conceptual understanding 
of the subject. It has previously been used to synthesise findings about medication-taking 
experiences, including in mental illness23.   
Data were extracted from the included articles in the form of first order constructs and second order 
constructs. First order constructs are examples of direct quotations from research participants, 
whilst second order constructs are the interpretations of these quotations offered by the original 
researchers. These definitions of first and second order constructs have been previously used in 
health research24. For each second order construct extracted from a paper, one or more first order 
constructs were collected in order to provide the reviewers with a clearer insight into the meanings. 
Tables of second order constructs were collated, which were developed by the authors into third 
order constructs – higher level interpretations of the second order constructs derived from the 
synthesis. Finally, these third order constructs were developed into an explanatory model of the key 
themes. 
 
Results 
Systematic Review 
Our search identified a total of 1985 titles and abstracts for screening, of which 26 were identified 
via hand searching of the bibliographies of key papers, with the rest identified via database search. 
Full-text articles were obtained for 54 papers. After assessment, 31 articles were found to meet our 
inclusion criteria. Figure 1 illustrates the systematic review process using a flowchart based on the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidance25. Table 1 
details the 31 articles selected for inclusion in the synthesis26-56, including their demographic data. 
The 31 studies selected for inclusion in our synthesis comprise studies of caregivers, paediatric 
patients and adult patients across seven different countries.  
Critical appraisal 
All assessed articles scored above 50% on the CASP rating and none were therefore excluded on 
grounds of poor quality. On assigning relevance scores, 13 papers were assigned as key papers and 
the remaining 18 designated satisfactory. These results are detailed in Table 1 (key papers denoted 
KP, satisfactory articles denoted SAT). It was noted that some included papers were supported by 
pharmaceutical industry funding and this has been presented in Table 1 to demonstrate the spread. 
 
Data Extraction and Synthesis 
In total, 31 second order constructs emerged from the original papers. These are detailed in Table 2, 
along with the articles from which they arise. Once the second order constructs had been 
established by the review team, these were discussed in meetings and mapped in a series of 
diagrams to develop third order constructs that describe the major themes shaping patients and 
caregivers’ experiences with medication. These are presented here and in order to more clearly 
describe our findings, have been used to categorise individual second order constructs: 
•   Coming to terms with ADHD 
•   Anticipated concerns about medication 
•   Experiences of the effects of medication  
•   External influences 
•   The development of self-management 
Coming to terms with ADHD 
For many caregivers, the diagnosis of ADHD was difficult to accept. Many papers noted that 
the decision to start medication was preceded by an acceptance of ADHD as a biological 
problem. Caregivers’ decisions about pharmacotherapy were also shaped by their beliefs 
about medication.  For patients, the process of coming to terms with ADHD was often 
reflected in how ADHD or medication impacted their sense of identity – as one college 
student stated: “I don’t like the idea . . . that the person I’m most like is the person who I am 
when I am taking medication . . . But I find more and more, that when I don’t take it, I don’t 
act as someone that I think that I am or who I’d like to be . . .” 50 . The fear of stigma was also 
commonly cited as a concern, particularly for parents and early on after receiving a 
diagnosis. A number of papers also described medications as a last resort in ADHD, 
considered a reasonable option only when other measures had been exhausted.  
Anticipated concerns about medication  
Both patients and caregivers had concerns about the long term impact of medication. One 
parent stated: “I don’t know how it’s [medication] going to affect him in the future? I don’t 
know how it will affect his kids”39.  Anticipated concerns also included short term worries 
such as fears about potential side effects before commencing medication as highlighted in 
this quote: “My fear is that he would kind of ‘zombie out.’”41. These anticipated concerns 
influenced decisions about whether or not to start or continue using ADHD medication. 
Many of these anticipated concerns were not grounded in any objective information from 
clinicians or scientific literature but came about from informal sources such as friends and 
family or the media. 
External influences  
Parents’ decisions to commence medication were often influenced by external parties, 
including family and friends, and school staff – “It was like the teachers were pushing me, 
pushing me. Get him meds, get him meds”35. The relative importance of external influences 
changed during treatment as the patient matured, as illustrated in Figure 2. For children 
(and their parents), media was a powerful force. In both children and adolescents, school 
staff played an important role and for adults, higher education and employment was an 
important factor. 
Experiences of the effects of medication  
The experience of both positive and negative effects of medication had a profound influence 
on patients and caregivers decisions about continuing medication. Patients and caregivers 
considered the balance of the benefits of medication against side effects, as well as the 
impact of untreated ADHD, which could equally have positive and negative domains. There 
were many examples of both physical and mental health effects of the medication. For some 
young people, the medications caused difficulties regarding their identity and also regarding 
control over their lives. For example one young person reported: “Like the tablets are taking 
over me and I can’t control myself, the tablets are in control of me.”54 
The development of self-management  
Several papers noted that the child’s involvement in medication decisions increased as they 
matured – as one adolescent said: “When I was younger, I didn’t have a whole lot of say-so 
in what was going on … It was just, ‘Take your medicine.’ As I got older, they started talking 
to me more … It got better as I got older”36.  In addition, many papers highlighted that 
caregivers and patients experimented with their medication regime in order to aid decision 
making. This process often culminated in patients using medication selectively to help them 
meet the demands placed upon them. As one college student put it: “It’s good for working 
but . . . I don’t really feel like being on it all the time I guess”50. 
Our synthesis demonstrates that medication-taking experiences are often represented as a series of 
‘trade-offs’. This theme recurred either explicitly or implicitly across several papers. When making 
decisions about medications, patients and caregivers balanced the benefits of medication against 
negative consequences including side-effects, stigma, and the impact of medication on identity.  The 
experience of medication-taking as a set of trade-offs was echoed both by patients and caregivers, 
and persisted throughout different age groups of patients.  Often this experience was a major driver 
towards the development of self-management, as patients chose to take their medication in a way 
that best balanced their own personal set of trade-offs.  
We developed an explanatory model depicting the interplay of several of the second and third order 
constructs in shaping the medication-taking experience.  The model illustrates the evolution of 
external influences on decisions about medication-taking as the patient and caregivers make their 
journey through treatment and as the patient matures. The coloured circles in the model show how 
the primary decision maker changes over time. Many papers highlighted that the parent or caregiver 
is originally the main decision maker with regard to medication, though they are influenced by the 
behaviours and opinions of the child. This relationship then moves to a pattern of shared decision 
making between the parent and the adolescent patient, illustrated in the second circle. Finally, the 
now adult patient may move to a position of self-management, becoming the primary decision 
maker in the third circle.  
This model also illustrates some of the external influences on decisions about medication, and how 
these influences can change over time.  Several included studies dealt with the initial decision to 
start medication to treat ADHD. This decision was most often taken by parents/caregivers, and was 
often influenced by pressures from school staff, and the opinion of family and friends. Parents were 
also influenced by the portrayal of both medication and ADHD in the media. In the adolescent phase, 
during which patients and caregivers negotiate whether to continue medication, patients are 
influenced by the opinions of their peers, and the opinions of school staff, family and friends remain 
important. However, the influence of media depictions of medication or ADHD seem to lose their 
influence at this stage. In the adult phase, when the patient moves towards a position of self-
managing their medication, the influence of varying academic or professional demands become 
more important. The relationship between patient, caregiver and healthcare professional plays a 
role at all stages.   
The concept of ‘trade-offs’ and the explanatory model combine to give a conceptual picture of the 
changing experience of medication-taking in ADHD. ‘Trade-offs’ are largely internal experiences that 
remain fairly constant throughout the stages of the treatment journey, even if different constructs 
bore more or less influence at different times. Conversely, the model of evolving decision making 
represents some of the external pressures, which change more consistently as the patient matures.  
The model is not intended to be a summary of the third order constructs identified in our synthesis; 
indeed it contains a combination of both second and third order constructs. The relationships 
between individual second and third order constructs are outlined in table 2, which also identifies 
the included papers that support them. Rather, it is intended to provide a conceptual summary of 
the complex and evolving processes involved in making decisions about medication-taking for ADHD, 
as well as illustrating the elements that were consistently highlighted by participants in the included 
studies.   
 
Discussion 
Summary 
This synthesis of qualitative studies of medication-taking in ADHD demonstrates that patients and 
caregivers’ experiences can be broadly described by 5 main themes; Coming to terms with ADHD, 
Anticipated concerns about medication, Experiences of the effects of medication, External influences 
and the development of self-management. In addition, the explanatory model described above 
illustrates that the experience of medication-taking transforms as the patient matures and the locus 
of decision making shifts from caregivers to patients. The longitudinal nature of this illustration 
demonstrates that in order to support patients in decision making, clinicians must tailor their 
interventions to the appropriate stage of their disease experience. 
Strengths and Limitations 
One of the limitations of this work is that we chose to combine data from studies involving children, 
adolescents, and adults. This may have prevented us from appreciating the subtleties of the 
different experiences of children and adults with ADHD. However, we have attempted to overcome 
by this by producing a longitudinal explanatory model, allowing readers to appreciate that 
experiences can vary considerably with age.  Whilst the explanatory model described in this paper 
depicts a medication-taking journey starting in childhood and continuing into adulthood, many key 
findings such as the role of trade-offs or the development of self-management could be relevant to 
patients with ADHD diagnosed and treated later in life. In addition, the majority of papers in this 
synthesis originated in the US, which could limit the generalisability of the findings to countries with 
different state health models and where drugs are less likely to be marketed directly to the public57.  
However, with evidence of increasing prescribing tendencies for ADHD in the UK58, a thorough 
understanding by clinicians of patients’ and carers’ concerns surrounding medication-taking 
becomes imperative.  The review team in this study included clinically trained researchers which 
strengthens the clinical focus to our investigation.  
Implications for Research and Practice 
This review demonstrates that decisions about initiating and persisting with medications for ADHD 
are highly complex and are affected by a variety of factors, both internal and external. These findings 
match the results of previous studies that have described the complexity of treatment decisions and 
the importance of both social, medical and treatment related factors12, 13, 59, . A previous review 
exploring non-adherence to pharmacological treatments also proposed a model to guide 
practitioners working with patients. It proposed three clinical actions: ensuring that patients have 
the right information, helping patients become motivated to commit to treatment, and assisting 
patients to overcome practical barriers60. These actions broadly fit with the model generated in this 
review, which contains additional, disease-specific information. The evolving nature of decision 
making as patients move into adulthood and the importance of educational and social functioning 
are particularly important features of adherence in ADHD compared to the broader adherence 
literature. 
Clinicians involved in ADHD management should be aware of the importance of these factors, and 
the fact that they evolve from predominantly parental concerns in childhood, to more autonomous 
decisions in adolescence and adulthood. It is particularly important for clinicians to recognise that 
these decisions often involve compromises. It is likely that for a given patient, there will factors that 
both encourage and discourage them towards a choice to take medications. In the case of ADHD, 
this may be especially relevant because of the variation in clinical guidelines internationally. By 
recognising this uncertainty, clinicians can allow individuals to voice their unease and consider all 
available options. Similarly, the relationships between patients and their caregivers evolves with 
time of life, as do the external influences on the individual and family unit. Clinicians can 
acknowledge this shifting dynamic and recognise the autonomy of adolescent patients by including 
them more in treatment decisions. Furthermore, they can probe individuals and families about 
family, peer, school, and employer factors according to the stage of development of the patient. By 
voicing the influencing factors and acknowledging them in discussions, patient-clinician discussions 
can focus on key areas that will help to shape treatment choices. 
Future research in this area might further explore the emerging family issues including sibling and 
parent dynamics and the types of media portrayals that influence perceptions of ADHD and its 
treatment. Although a proportion of papers included in this study were funded by pharmaceutical 
industry funding, a more detailed analysis of the effect of this funding was beyond the scope of this 
review and might be investigated in further studies. In addition, a clinical tool to help support 
decision-making could also be developed and tested, using the findings from this review.  
This synthesis conceptualises the evolving experiences of using medications for ADHD. Consideration 
of these findings by clinicians may allow better engagement with both patients and caregivers to 
support shared decision making. 
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Table 1: Characteristics of Articles Included in the Meta-Ethnography 
Number Author, Year 
Study 
Population 
Sample Size Age of ADHD 
patients 
Recruitment Setting Country Methods Relevance 
Pharmaceutical 
Funding 
126 Ahmed et al., 2013 Parents 
3 focus groups 
Not stated Recruitment agency Australia Focus groups KP No 
227 Ahmed et al., 2014 Parents 
3 focus groups Range 3-12 at 
diagnosis 
Recruitment agency Australia Focus groups SAT No 
328 
Avisar & Lavie-Ajayi, 
2014  
Adolescents 
14 interviews 
Range 12.5-16.5 
Private practice & 
acquaintances 
Israel 
Semi-structured 
interviews 
KP Not stated 
429 
Brinkman et al., 
2009 
Parents 
12 focus groups 
Range 6-17 
Community paediatric 
clinic 
USA Focus groups KP Yes 
530 
Brinkman et al., 
2012 
Adolescents 
7 focus groups 
Mean 15.1 
Community paediatric 
clinic 
USA Focus groups KP Yes 
631 
Bull & Whelan, 
2006 
Parents 
10 interviews 
Range 5-15 ADHD support group Australia 
Semi-structured 
interviews 
SAT Not stated 
732 Charach et al., 2006 Parents 
3 focus groups 
Range 7-15 Specialty clinic Canada Focus groups KP No 
833 Charach et al., 2014 
Parents and 
Adolescents 
24 interviews 
Range 12-15 Specialty clinic Canada 
Semi-structured 
interviews 
KP No 
934 Cheung et al., 2015 
Young Adults 
with ADHD 
40 interviews 
Range 16-23 
Paediatric and child 
psychiatry 
departments 
Hong Kong 
Semi-structured 
interviews 
SAT Yes 
1035 Coletti et al., 2012 Parents 
5 focus groups 
Mean 9.35 Child psychiatry clinic USA Focus groups KP Not stated 
1136 Cormier, 2012 Parents 
16 interviews 
Range 6-11 ADHD support group USA 
Semi-structured 
interviews 
KP No 
1237 Davis, 2011 Parents 
28 interviews 
Range 6-15 
San Diego ADHD 
project 
USA 
Semi-structured 
interviews & survey 
SAT No 
1338 dosReis et al., 2009 Parents 
48 interviews Mean 8.8                                  
Range 6-16 
Primary care and 
specialty clinics 
USA 
Semi-structured 
interviews 
SAT No 
1439 
Hansen & Hansen, 
2006 
Parents 
10 interviews 
Range 8-22 
Secondary care and 
ADHD advocacy group 
Canada 
Semi-structured 
interviews 
KP Not stated 
1540 
Jackson & Peters, 
2008 
Parents 
10 interviews 
Range 7-18 Larger study Not stated Interviews KP Not stated 
1641 Knipp, 2006 Adolescents 
15 interviews 
Not stated High school USA Interviews SAT No 
  
1742 
Leggett & Hotham, 
2011 
Parents and 
Adolescents 
35 interviews Mean 11.5                         
Range 6-17     
Paediatric clinics Australia 
Interviews and semi-
structured questionnaire 
SAT No 
1843 Leslie et al., 2007 Parents 
28 interviews Mean 9.5                            
Range 6-16 
Primary care USA 
Semi-structured 
interviews 
SAT No 
1944 Loe & Cuttino, 2011 
College 
students 
16 interviews Mean 20.75                       
Range 19-22 
Private liberal arts 
college 
USA Interviews SAT No 
2045 
Matheson et al., 
2013 
Adults with 
ADHD 
30 interviews Mean 34.9                         
Range 18-57 
Outpatient clinic and 
ADHD charity 
UK 
Semi-structured 
interviews and survey 
SAT Yes 
2146 Meaux et al., 2006 
College 
students 
15 interviews 
Range 18-21 University USA 
Semi-structured 
interviews 
KP Not stated 
2247 Mills, 2011 Parents 
19 interviews 
Not stated School district USA 
Semi-structured 
interviews 
KP Not stated 
2348 O'Callaghan, 2014 
Adults with 
ADHD 
18 interviews 
Range 19-64 
ADHD mentoring 
scheme and support 
group 
Not stated 
Semi-structured 
interviews 
SAT Not stated 
2449 Searight, 1996 Children 
25 interviews  
Range 5-16 Paediatric ADHD clinic USA 
Interviews and 
ethnographic inquiry 
SAT Not stated 
2550 Sikirica et al., 2014 
Parents and 
Adolescents 
66 interviews Mean 11.9                
Range 6-17 
Online panel 
8 European 
countries 
Semi-structured 
interviews 
SAT Yes 
2651 Singh, 2003 
Parents 
(fathers) 
61 interviews Mean 9.5                  
Range 6-12 
Secondary care clinic USA 
Interviews using a picture-
based method 
SAT Not stated 
2752 Singh et al., 2010 Adolescents 
16 interviews  
Range 9-14 Secondary care UK 
Focus groups and one-one 
interviews 
KP No 
2853 Taylor et al., 2007 Parents 
33 interviews 
Not stated 
University database 
and ADHD support 
group 
Australia 
Semi-structured 
interviews 
SAT No 
2954 
Travell & Visser, 
2006 
Parents and 
children 
17 interviews 
Range 11-16 
Local education 
authority 
UK 
Semi-structured 
interviews 
SAT Not stated 
3055 
Walker-Noack et al., 
2009 
Youth aged 
10-21 
6 focus groups Mean 14.3                
Range 10-21 
Schools  Canada Focus groups SAT No 
3156 Wong et al., 2009 
Young adults 
aged 15-24 
15 interviews Mean 18.2                
Range 15-24 
Paediatric and child 
and adult mental 
health clinics 
UK In depth interviews SAT Not stated 
  
Table 2: Third Order Constructs  
Second order construct Articles 
Coming to terms with ADHD 
Varying parental understanding of ADHD 2, 4, 7, 10, 11, 15, 18, 19, 22, 26, 28 
Intrinsic beliefs about medication 4, 7, 12, 13, 17, 22, 25, 26, 27, 31 
Coming to terms with the diagnosis 4, 11, 22, 28 
Fear of stigma 4, 7, 10, 11, 21, 27, 30 
Considering medication as a last resort 4, 7, 8, 10, 11, 15, 18, 22, 28 
Anticipated concerns about medication 
Fear of addiction 1, 4, 18, 25 
Concerns about long term consequences of 
medication 
1, 2, 8, 14, 28 
Concerns about anticipated side effects 2, 4, 6, 7, 9, 11, 17, 23 
Worries about the financial cost of medication 18, 25 
External influences 
Influence of family and friends 1, 4, 7, 15, 18, 22 
Influence of the media 2, 4, 7, 15, 22, 28 
Content of information provided 2, 10, 11, 12, 31 
Relationships with health professionals 1, 4, 10, 18, 20, 21, 23, 28, 31 
Child-parent relationship 3, 5, 22, 31 
Relationships with school staff 4, 15, 28, 29, 31 
Spousal conflicts 4, 7, 22, 28 
Experiences of misuse of ADHD medications 21 
Experiences of the effects of medication 
Functional 
effects of 
medication 
Impact on behaviour 1, 11, 14, 15, 27, 30 
Impact on academic performance 1, 3, 5, 6, 8, 9, 10, 11, 14, 16, 17, 21, 23, 27, 30, 31 
Impact on social skills & interpersonal 
relationships 
1, 3, 5, 8, 10, 16, 17, 20, 21, 23 
Impact on creativity 5, 23 
Functional impact of untreated ADHD 1, 4, 5, 9, 10, 18, 22, 23, 24, 27, 30, 31 
Experiences of actual side effects 1, 3, 6, 7, 8, 9, 14, 15, 18, 21, 24, 25, 29, 30, 31 
The development of self-management 
Situational use of medication 1, 5, 10, 19, 20, 21, 25 
Persistent doubts about medication use 4, 14, 22 
Experimenting with medication regime 4, 5, 7, 10, 14, 21, 28, 31 
Developing autonomy as an individual 3, 5, 8, 29 
Making future plans for medications 14, 19, 25, 27, 31 
Finding alternatives to medications 19, 20 
Consideration of trade-offs 3, 5, 7, 8, 11, 12, 14, 16, 19, 20, 21, 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
